Chinese Herbal Medicine as a Novel Paradigm for Cancer Chemotherapy
Chinese Herbal Medicine as a Novel Paradigm for Cancer Chemotherapy
批准号:
9146289
负责人:
YUNG-CHI CHENG
金额:
$87.78万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2011
资助国家:
美国
项目状态:
已结题
起止时间:
2011-09-15 至 2018-08-31
关键词:
AddressAntineoplastic AgentsBioinformaticsBiologicalBiological MarkersBiometryBotanicalsCamptothecin-11ChemicalsChemotherapy-Oncologic ProcedureChinese HerbsClinicalClinical InvestigatorClinical ResearchClinical TrialsColorectal CancerComplexComputing MethodologiesCyclic GMPDataDevelopmentDiarrheaDoctor of MedicineDoctor of PhilosophyDouble-Blind MethodEnsureFingerprintFoundationsGene ExpressionGoalsGrantHerbal MedicineHumanMalignant NeoplasmsMediatingMedicineMethodologyMethodsMiningNatural ProductsNatureNausea and VomitingNormal tissue morphologyPHY 906PatientsPhasePlacebo ControlPlacebo EffectPlacebosPlasmaPreparationProceduresProcessProgram Research Project GrantsProgression-Free SurvivalsQuality ControlQuality of lifeRandomizedRegulationResearch DesignResearch PersonnelRoleSafetySeriesSiteStatistical MethodsSystems BiologyTestingTopoisomerase-I InhibitorToxic effectTreatment Protocolsarmbasecancer therapychemokinechemotherapyclinical efficacycohesioncytokinedata miningdesignexperiencehealth related quality of lifeimprovedin vivoinnovationinterdisciplinary approachirinotecanmeetingsmetastatic colorectalnoveloxaliplatinpatient subsetspharmacodynamic biomarkerphase 2 studyplacebo controlled studypreclinical studypredictive markerprogramsresponsestandard of caretooltumor
中文摘要
点击翻译按钮获取中文摘要
英文摘要
This is a revised clinical- and translational-based interdisciplinary Program Project Grant application entitled "Chinese Herbal Medicine as a Novel Paradigm for Cancer Chemotherapy". The Pl of this Program is Yung-chi Cheng, Ph.D., and he directs Project 2. He is joined two other well-established Project leaders, Edward Chu, M.D. (Project 1), who also serves as Co-P.l. of the Program, and Hongyu Zhao, Ph.D. (Project 3). These 3 Projects are supported by an Administrative Core (Core A) and an Analytical Core (Core B). In this application, we propose to investigate PHY906, a Chinese herbal medicine that has been used in the Orient for nearly 2000 years. Our group has developed a rigorous standard operating procedure to produce cGMP material as well as develop highly sensitive chemical (LC-MS) and biological (gene expression) fingerprinting methodologies to ensure quality control and consistency of batch preparation. Using high quality cGMP material, we plan to conduct a randomized, double-blind, placebo-controlled study where PHY906 will be tested in combination with the topoisomerase I inhibitor irinotecan (CPT-11) in patients with mCRC in the 2nd- line setting. In Project 1, Dr. Chu will investigate the effect of PHY906 on the safety, health-related quality of life, and clinical efficacy of CPT-11 monotherapy. In Project 2, Dr. Cheng will conduct an extensive series of biomarker analyses to identify the potential pharmacodynamic markers that can be used to predict for the clinical activity and efficacy of PHY906 when used in combination with CPT-11. In Project 3, Dr. Zhao will develop novel bioinformatic and computational methodologies to mine the translational data coming from Project 2 with the goal of identifying the predictive biomarkers that are associated with either the cytoprotective effects of PHY906 on CPT-11 toxicity and/or the modulatory effects of PHY906 on clinical efficacy of CPT-11 chemotherapy, as determined by the studies proposed in Project 1. Several mechanisms are in place to ensure the close interaction and cohesion of the Program, and these include monthly meetings of the Project leaders, an annual retreat, and an internal advisory board to provide guidance and advice.
期刊论文(13)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
DOI:
10.1186/1472-6882-14-490
发表时间:
2014-12-15
期刊:
BMC complementary and alternative medicine
影响因子:
--
作者:
[Lam W, Jiang Z, Guan F, Hu R, Liu SH, Chu E, Cheng YC]
通讯作者:
Cheng YC
DOI:
10.1186/s12943-018-0800-6
发表时间:
2018-02-19
期刊:
Molecular cancer
影响因子:
37.3
作者:
[Tan HY, Wang N, Lam W, Guo W, Feng Y, Cheng YC]
通讯作者:
Cheng YC
Study of Malformin C, a Fungal Source Cyclic Pentapeptide, as an Anti-Cancer Drug.
真菌源环状五肽 Malformin C 作为抗癌药物的研究。
DOI:
10.1371/journal.pone.0140069
发表时间:
2015
期刊:
PloS one
影响因子:
3.7
作者:
[Wang,Jing, Jiang,Zaoli, Lam,Wing, Gullen,ElizabethA, Yu,Zhe, Wei,Ying, Wang,Lihui, Zeiss,Caroline, Beck,Amanda, Cheng,Ee-Chun, Wu,Chunfu, Cheng,Yung-Chi, Zhang,Yixuan]
通讯作者:
Zhang,Yixuan
DOI:
10.1007/s40264-014-0250-z
发表时间:
2015-02
期刊:
DRUG SAFETY
影响因子:
4.2
作者:
[Liu, Shwu-Huey, Chuang, Wu-Chang, Lam, Wing, Jiang, Zaoli, Cheng, Yung-Chi]
通讯作者:
Cheng, Yung-Chi
DOI:
10.1038/s41598-018-25813-x
发表时间:
2018-05-09
期刊:
Scientific reports
影响因子:
4.6
作者:
[Guan F, Lam W, Hu R, Kim YK, Han H, Cheng YC]
通讯作者:
Cheng YC
共 10 条
Chinese Herbal Medicine as a Novel Paradigm for Cancer Chemotherapy
-
批准号:8175586
-
项目类别:
-
资助金额:$134.06万
-
财政年份:2011
-
负责人:YUNG-CHI CHENG
-
依托单位:
Administration Core
-
批准号:8555272
-
项目类别:
-
资助金额:$10.35万
-
财政年份:2011
-
负责人:YUNG-CHI CHENG
-
依托单位:
Characterization of Predictive Biomarkers for the Clinical Efficacy of PHY906
-
批准号:8920509
-
项目类别:
-
资助金额:$18.87万
-
财政年份:2011
-
负责人:YUNG-CHI CHENG
-
依托单位:
Chinese Herbal Medicine as a Novel Paradigm for Cancer Chemotherapy
-
批准号:8528511
-
项目类别:
-
资助金额:$121.48万
-
财政年份:2011
-
负责人:YUNG-CHI CHENG
-
依托单位:
Chinese Herbal Medicine as a Novel Paradigm for Cancer Chemotherapy
-
批准号:8727468
-
项目类别:
-
资助金额:$124.68万
-
财政年份:2011
-
负责人:YUNG-CHI CHENG
-
依托单位:
Characterization of Predictive Biomarkers for the Clinical Efficacy of PHY906
-
批准号:8555271
-
项目类别:
-
资助金额:$53.26万
-
财政年份:2011
-
负责人:YUNG-CHI CHENG
-
依托单位:
Chinese Herbal Medicine as a Novel Paradigm for Cancer Chemotherapy
-
批准号:8333321
-
项目类别:
-
资助金额:$129.24万
-
财政年份:2011
-
负责人:YUNG-CHI CHENG
-
依托单位:
Chinese Herbal Medicine as a Novel Paradigm for Cancer Chemotherapy
-
批准号:8920507
-
项目类别:
-
资助金额:$46.13万
-
财政年份:2011
-
负责人:YUNG-CHI CHENG
-
依托单位:
Administration Core
-
批准号:8920511
-
项目类别:
-
资助金额:$3.69万
-
财政年份:2011
-
负责人:YUNG-CHI CHENG
-
依托单位:
Nucleoside Analogs as Anticancer Compounds
-
批准号:7911052
-
项目类别:
-
资助金额:$9.9万
-
财政年份:2009
-
负责人:YUNG-CHI CHENG
-
依托单位:
Mechanism and in vivo anti-HBV study of a novel class of non-nucleoside compounds
-
批准号:7772361
-
项目类别:
-
资助金额:$36.16万
-
财政年份:2007
-
负责人:YUNG-CHI CHENG
-
依托单位:
Research Programs-Developmental Therapeutics
-
批准号:7513242
-
项目类别:
-
资助金额:$2.16万
-
财政年份:2007
-
负责人:YUNG-CHI CHENG
-
依托单位:
Mechanism and in vivo anti-HBV study of a novel class of non-nucleoside compounds
-
批准号:7386552
-
项目类别:
-
资助金额:$36.5万
-
财政年份:2007
-
负责人:YUNG-CHI CHENG
-
依托单位:
Mechanism and in vivo anti-HBV study of a novel class of non-nucleoside compounds
-
批准号:7241099
-
项目类别:
-
资助金额:$37.13万
-
财政年份:2007
-
负责人:YUNG-CHI CHENG
-
依托单位:
Mechanism and in vivo anti-HBV study of a novel class of non-nucleoside compounds
-
批准号:7587471
-
项目类别:
-
资助金额:$36.53万
-
财政年份:2007
-
负责人:YUNG-CHI CHENG
-
依托单位:
NUCLEOSIDE ANALOGS AS ANTICANCER COMPOUNDS
-
批准号:2895111
-
项目类别:
-
资助金额:$22.94万
-
财政年份:1996
-
负责人:YUNG-CHI CHENG
-
依托单位:
Nucleoside Analogs as Anticancer Compounds
-
批准号:6745630
-
项目类别:
-
资助金额:$27.14万
-
财政年份:1996
-
负责人:YUNG-CHI CHENG
-
依托单位:
Nucleoside Analogs as Anticancer Compounds
-
批准号:7380601
-
项目类别:
-
资助金额:$15.0万
-
财政年份:1996
-
负责人:YUNG-CHI CHENG
-
依托单位:
Nucleoside Analogs as Anticancer Compounds
-
批准号:7917406
-
项目类别:
-
资助金额:$70.27万
-
财政年份:1996
-
负责人:YUNG-CHI CHENG
-
依托单位:
Nucleoside Analogs as Anticancer Compounds
-
批准号:7476316
-
项目类别:
-
资助金额:$46.83万
-
财政年份:1996
-
负责人:YUNG-CHI CHENG
-
依托单位:
海外基金